| Day 1, Thursday, May 14th | |
|---|---|
| 08:00–09:15 | Re-defining frontline myeloma therapy: The emerging role of BCMA-directed strategies in newly diagnosed multiple myeloma Pre-COMy CME Symposium by Springer |
| 09:15–09:25 | 🎤 COMy 2026 kick-off |
| 09:25–10:40 | Session 1: Advances in biology |
| 10:40–11:00 | ☕ Coffee Break |
| 11:00–12:15 | Session 2: New response criteria |
| 12:15–13:30 | Improving the journey: Patient-focused advances with CD38 mAb quadruplet therapy Industry-supported Symposium by Sanofi |
| 13:30–14:00 | 🍽️ Lunch Break |
| 14:00–15:15 | Interlacing evidence and practice: a 360-degree view on treating NDMM in 2026 Industry-supported Symposium by J&J |
| 15:15–16:30 | Session 3: Mechanisms of resistance |
| 16:30–16:50 | ☕ Coffee Break |
| 16:50–18:05 | Session 4: Plenary lectures I |
| 18:05–19:00 | Session 5: How to manage high risk disease |
| 19:00 | Welcome Reception |
| Day 2, Friday, May 15th | |
|---|---|
| 07:00–08:00 | Session 6: Webinar showcase from IACH I |
| 08:00–09:15 | Clinical Application of clonoSEQ Testing in multiple myeloma Industry-supported Symposium by Adaptive |
| 09:15–10:30 | Medical Crossfire: Turning Therapeutic Innovation Into Practice-Personalizing Care in Multiple Myeloma CME Symposium by PER |
| 10:30–10:50 | ☕ Coffee Break |
| 10:50–12:05 | Session 7: Cure: hope, hype or reality? |
| 12:05–13:20 | The red thread of innovation: emerging data and strategies in RRMM treatment Industry-supported Symposium by J&J |
| 13:20–13:50 | 🍽️ Lunch Break |
| 13:30-13:45 | Session 8: Webinar showcase from IACH II |
| 13:50–14:25 | Session 9: COMy Awards and lecture series |
| 14:25–15:40 | Debating the future of RRMM: What is best for our patients Industry-supported Symposium by Gilead and Kite |
| 15:40–16:40 | Session 10: IMS Session – Multiple myeloma: is cure on the horizon? |
| 16:40–17:55 | Unmet Needs in RRMM: Evolving BsAb Therapy From Inpatient to Outpateint Settings Industry-supported Symposium by Pfizer |
| 17:55–18:15 | ☕ Coffee Break |
| 18:15–19:45 | Session 11: State-of-the-art management |
| 19:45–20:15 | Session 12: Whats’s new at aIACH: educational tools for your clinical day-to-day |
| Day 3, Saturday, May 16th | |
|---|---|
| 07:00–08:00 | Session 13: Clinical cases |
| 08:00–09:15 | MRD 2.0 : Minimal Invasion, Maximum Insight Industry-supported Symposium by Sebia |
| 09:15–10:30 | Redefining Myeloma Care: An Expert Roundtable on the Potential of Novel Strategies Across the Disease Spectrum CME Symposium by Decera Clinical Education |
| 10:30–10:50 | ☕ Coffee Break |
| 10:50–12:00 | Session 14: The hard-to-treat-patients |
| 12:00–13:15 | The Evolving Role of ADC-Based BCMA Targeting in RRMM: Edvidence-Led Practicalities of Early Intervention Industry-supported Symposium by GSK |
| 13:15–13:45 | 🍽️ Lunch Break |
| 13:25-13:40 | Session 15: Webinar showcase from IACH IIII |
| 13:45–14:50 | Session 16: COMy debates |
| 14:50–16:05 | Advancing RRMM Care With T-cell Redirecting Therapies: Current Landscape and Future Directions Industry-supported Symposium by BMS |
| 16:05–17:20 | Beyond Head-to-Head Trials: Answering Real Myeloma Questions – What Matching-Adjusted Indirect Comparisons (MAICs) Show and What They Don’t Industry-supported Symposium by Regeneron |
| 17:20–17:30 | ☕ Coffee Break |
| 17:30–19:30 | Session 17: Plenary lectures II |
| 19:30-20:00 | Session 18: COMy in-person conclusions |
| Day 4, Sunday, May 17th – ONLINE-ONLY | |
|---|---|
| 10:00–11:05 | Multiple Myeloma Communications I |
| 11:05–11:15 | ☕ Break |
| 11:15–12:20 | Multiple Myeloma Communications II |
| 12:20–12:30 | Conclusions and see you next year! |
